Workflow
高分子材料助剂
icon
Search documents
股市必读:呈和科技(688625)7月23日董秘有最新回复
Sou Hu Cai Jing· 2025-07-23 21:01
截至2025年7月23日收盘,呈和科技(688625)报收于30.98元,下跌1.96%,换手率0.95%,成交量1.8万 手,成交额5632.3万元。 董秘最新回复 投资者: 万华化学2026年准备生产的成核剂跟公司产品类似吗?生产以后会不会对公司的利润产生影 响?万华的订单占公司的比例高吗? 董秘: 尊敬的投资者,您好,公司的成核剂产品具备自主知识产权,通过全球主要国家或地区颁布的 食品接触法规与标准、取得全球聚丙烯装置工艺技术Novolen、Unipol和LyondellBasell的技术准入资 格。质量达到国际先进水平,产品研发、生产的创新迭代能力强,能够根据客户需求为客户提供技术领 先的高分子材料助剂产品及定制化的配套分析服务。主要客户包括中国石化、中国石油、中海壳牌、延 长石油、北欧化工、博禄化工等国内外大型能源化工企业。感谢您对公司的关注和支持! 当日关注点 交易信息汇总:7月23日主力资金净流出742.97万元,占总成交额13.19%。 交易信息汇总 7月23日,呈和科技的资金流向情况如下:主力资金净流出742.97万元,占总成交额13.19%;游资资金 净流入251.65万元,占总成交额4. ...
拟收购柔性印制电路板企业的PCB概念股年内涨100% 4月披露并购重组进展的A股名单一览
Xin Lang Cai Jing· 2025-05-01 03:07
Group 1 - Mergers and acquisitions (M&A) are important market tools supporting economic transformation and high-quality development, with a significant focus on technological innovation [1] - The current round of M&A respects market rules and has fully mobilized the enthusiasm of listed companies to participate [1] - Cross-industry mergers and vertical integration of industrial chains are becoming new opportunities for listed companies to break through [1] Group 2 - A total of 86 A-share listed companies have disclosed M&A progress since April, excluding ST and failed restructurings [2] - Notable companies involved in M&A include Shenyang Machine Tool, Binhai Energy, and China Shipbuilding, among others [2] - The disclosed M&A activities include various types of transactions such as capital increases, asset acquisitions, and mergers [4][5][6] Group 3 - Xunjie Technology plans to acquire 100% equity of Shenzhen Jiahong Electronics through share issuance and cash payment, enhancing its position in the flexible printed circuit board sector [6] - Chenghe Technology intends to acquire at least 51% of Yuhua Yingri Technology, with an estimated valuation of 1.8 billion RMB, aiming to strengthen its presence in the display materials market [8] - Sunshine Nuohe plans to acquire 100% of Jiangsu Langyan Life Science Technology through share issuance and convertible bonds, focusing on drug research and development [10]